Search Results

There are 7656 results for: content related to: Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

  1. You have full text access to this OnlineOpen article
    Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 5, May 2014, Pages: 467–477, T. Forst, R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger and P. Stein

    Article first published online : 12 MAR 2014, DOI: 10.1111/dom.12273

  2. You have full text access to this OnlineOpen article
    Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 2, February 2015, Pages: 188–197, S. Sha, D. Polidori, K. Farrell, A. Ghosh, J. Natarajan, N. Vaccaro, J. Pinheiro, P. Rothenberg and L. Plum-Mörschel

    Article first published online : 5 JAN 2015, DOI: 10.1111/dom.12418

  3. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 10, October 2014, Pages: 1016–1027, J.-F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue, E. Wajs, K. Figueroa, J. Jiang, G. Law, K. Usiskin, G. Meininger and on behalf of the DIA3004 Study Group

    Article first published online : 22 JUL 2014, DOI: 10.1111/dom.12348

  4. You have full text access to this OnlineOpen article
    Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 4, April 2013, Pages: 372–382, K. Stenlöf, W. T. Cefalu, K.-A. Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel and G. Meininger

    Article first published online : 24 JAN 2013, DOI: 10.1111/dom.12054

  5. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 3, May/June 2015, Pages: 226–236, Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Donna Skee, Ewa Wajs, Rao N. V. S. Mamidi, Hong Tian, An Vandebosch, Shean-Sheng Wang, Tom Verhaeghe, Hans Stieltjes and Keith Usiskin

    Article first published online : 27 OCT 2014, DOI: 10.1002/cpdd.166

  6. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 3, March 2015, Pages: 294–303, B. Bode, K. Stenlöf, S. Harris, D. Sullivan, A. Fung, K. Usiskin and G. Meininger

    Article first published online : 12 JAN 2015, DOI: 10.1111/dom.12428

  7. You have free access to this content
    Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 6, June 2012, Pages: 539–545, D. Devineni, L. Morrow, M. Hompesch, D. Skee, A. Vandebosch, J. Murphy, K. Ways and S. Schwartz

    Article first published online : 8 FEB 2012, DOI: 10.1111/j.1463-1326.2012.01558.x

  8. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 1, January 2015, Pages: 23–31, L. Ji, P. Han, Y. Liu, G. Yang, N. K. Dieu Van, U. Vijapurkar, R. Qiu and G. Meininger

    Article first published online : 14 OCT 2014, DOI: 10.1111/dom.12385

  9. You have full text access to this OnlineOpen article
    Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

    Annals of the New York Academy of Sciences

    Volume 1358, Issue 1, November 2015, Pages: 28–43, Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel and Keith Demarest

    Article first published online : 25 AUG 2015, DOI: 10.1111/nyas.12852

  10. You have full text access to this OnlineOpen article
    Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

    Journal of the American Geriatrics Society

    Volume 64, Issue 3, March 2016, Pages: 543–552, Alan J. Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai and Gary Meininger

    Article first published online : 21 MAR 2016, DOI: 10.1111/jgs.14028

  11. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 11, November 2014, Pages: 1087–1095, S. Sha, D. Polidori, T. Heise, J. Natarajan, K. Farrell, S.-S. Wang, D. Sica, P. Rothenberg and L. Plum-Mörschel

    Article first published online : 8 JUL 2014, DOI: 10.1111/dom.12322

  12. You have full text access to this OnlineOpen article
    Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 5, May 2013, Pages: 463–473, J.-F. Yale, G. Bakris, B. Cariou, D. Yue, E. David-Neto, L. Xi, K. Figueroa, E. Wajs, K. Usiskin and G. Meininger

    Article first published online : 27 MAR 2013, DOI: 10.1111/dom.12090

  13. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 4, July/August 2015, Pages: 295–304, Damayanthi Devineni, Joseph Murphy, Shean-Sheng Wang, Hans Stieltjes, Paul Rothenberg, Ellen Scheers and Rao N.V.S. Mamidi

    Article first published online : 11 DEC 2014, DOI: 10.1002/cpdd.162

  14. You have free access to this content
    Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus

    The Journal of Clinical Hypertension

    Volume 16, Issue 12, December 2014, Pages: 875–882, Matthew R. Weir, Andrzej Januszewicz, Richard E. Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung and Gary Meininger

    Article first published online : 20 OCT 2014, DOI: 10.1111/jch.12425

  15. You have full text access to this OnlineOpen article
    Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1136–1145, N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta and H. Kuki

    Article first published online : 14 JUL 2013, DOI: 10.1111/dom.12149

  16. You have full text access to this OnlineOpen article
    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

    International Journal of Clinical Practice

    Volume 67, Issue 12, December 2013, Pages: 1267–1282, J. P. H. Wilding, G. Charpentier, P. Hollander, G. González-Gálvez, C. Mathieu, F. Vercruysse, K. Usiskin, G. Law, S. Black, W. Canovatchel and G. Meininger

    Article first published online : 13 OCT 2013, DOI: 10.1111/ijcp.12322

  17. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 4, July/August 2015, Pages: 279–286, Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Hans Stieltjes, Jay Ariyawansa, Nicholas A. Di Prospero and Paul Rothenberg

    Article first published online : 11 DEC 2014, DOI: 10.1002/cpdd.151

  18. You have free access to this content
    Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus

    Journal of the American Association of Nurse Practitioners

    Volume 26, Issue 7, July 2014, Pages: 356–363, Courtney S. Davis, Joshua W. Fleming and , & Laurie E. Warrington

    Article first published online : 4 JUN 2014, DOI: 10.1002/2327-6924.12135

  19. You have full text access to this OnlineOpen article
    The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

    International Journal of Clinical Practice

    Volume 69, Issue 10, October 2015, Pages: 1071–1087, S. A. Brunton

    Article first published online : 5 JUL 2015, DOI: 10.1111/ijcp.12675

  20. You have full text access to this OnlineOpen article
    Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

    The Journal of Clinical Pharmacology

    Volume 53, Issue 6, June 2013, Pages: 601–610, Damayanthi Devineni, Christopher R. Curtin, David Polidori, Maria J. Gutierrez, Joseph Murphy, Sarah Rusch and Paul L. Rothenberg

    Article first published online : 14 MAY 2013, DOI: 10.1002/jcph.88